Eledon Pharmaceuticals In... (ELDN)
NASDAQ: ELDN
· Real-Time Price · USD
2.62
0.02 (0.77%)
At close: Aug 15, 2025, 3:48 PM
Eledon Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 192K | n/a | n/a | n/a | 560K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 120.00 | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 97K | 95K | 94K | 94K | 94K | 92K | 93K | 93K | 94K | 93K | 61K | 44K | 44K | 46K |
Gross Profit | n/a | 192K | n/a | -97K | -95K | 466K | -94K | -94K | -92K | -93K | -93K | -94K | -93K | -60.88K | -44K | -44K | -46K |
Operating Income | -17.96M | -24.5M | -20.51M | -14.5M | -10.87M | -10.34M | -11.2M | -10.35M | -11.11M | -58.69M | -10.6M | -9.28M | -9.86M | -9.38M | -10.51M | -7.97M | -9.01M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -6.5M | -44.19M | 76.97M | -44.91M | -10.29M | -9.63M | -10.35M | -9.58M | -10.77M | -58.38M | -10.47M | -9.25M | -9.86M | -9.38M | -10.5M | -7.97M | -9M |
Net Income | -6.5M | -44.62M | 76.97M | -44.91M | -10.29M | -9.63M | -10.35M | -9.58M | -10.43M | -58.05M | -10.34M | -9.21M | -9.87M | -8.81M | -9.82M | -7.38M | -8.5M |
Selling & General & Admin | 4.43M | 6.77M | 3.99M | 4.4M | 3.36M | 3.18M | 3.27M | 3.15M | 3M | 2.79M | 3.15M | 3.54M | 3.22M | 3.2M | 2.85M | 3.73M | 3.35M |
Research & Development | 13.53M | 17.93M | 16.52M | 10.11M | 7.41M | 7.07M | 7.93M | 7.2M | 8.11M | 7.25M | 7.45M | 5.74M | 6.63M | 6.18M | 7.66M | 4.24M | 5.65M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 36K | -5K | n/a | 3K | -1K | 5K |
Operating Expenses | 17.96M | 24.7M | 20.51M | 14.5M | 10.77M | 10.24M | 11.2M | 10.35M | 11.11M | 10.04M | 10.6M | 9.28M | 9.86M | 9.38M | 10.51M | 7.97M | 9.01M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 338K | n/a | n/a | n/a | n/a | n/a | n/a | 5K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | -95K | -94K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 24.7M | 20.51M | 14.5M | 10.87M | 10.34M | 11.2M | 10.35M | 11.11M | 10.04M | 10.6M | 9.28M | 9.86M | 9.38M | 10.51M | 7.97M | 9.01M |
Income Tax Expense | n/a | -431K | n/a | n/a | 51.72K | 50.19K | n/a | -28.09K | -338K | -335K | -127K | -36K | 5K | -579K | -686K | -588K | -501K |
Shares Outstanding (Basic) | 77.13M | 59.79M | 51.95M | 42.28M | 29.99M | 24.21M | 29.97M | 24.01M | 14.29M | 13.78M | 14.27M | 14.27M | 14.33M | 14.31M | 14.82M | 14.82M | 14.83M |
Shares Outstanding (Diluted) | 771.27M | 59.79M | 55.48M | 42.28M | 29.99M | 24.21M | 29.97M | 24.01M | 14.29M | 13.78M | 14.27M | 14.27M | 14.33M | 14.82M | 14.82M | 14.82M | 14.83M |
EPS (Basic) | -0.08 | 1.04 | -0.34 | -1.06 | -0.34 | -0.4 | -0.35 | -0.4 | -0.73 | -4.21 | -0.73 | -0.65 | -0.69 | -0.62 | -0.66 | -0.5 | -0.57 |
EPS (Diluted) | -0.08 | 0.10 | -0.32 | -1.06 | -0.34 | -0.4 | -0.35 | -0.4 | -0.73 | -4.21 | -0.73 | -0.65 | -0.69 | -0.59 | -0.66 | -0.5 | -0.57 |
EBITDA | -17.96M | -24.61M | -20.43M | -14.4M | -10.77M | -10.24M | -11.1M | -10.26M | -11.02M | -9.95M | -10.51M | -9.19M | -9.77M | -9.32M | -10.46M | -7.93M | -8.96M |
EBIT | n/a | -24.7M | -20.51M | -14.5M | -10.87M | -10.34M | -11.2M | -10.35M | -11.11M | -10.04M | -10.6M | -9.28M | -9.86M | -9.38M | -10.51M | -7.97M | -9.01M |
Depreciation & Amortization | n/a | 88K | 79K | 97K | 95K | 94K | 94K | 94K | 92K | 93K | 93K | 94K | 93K | 61K | 44K | 44K | 46K |